Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

被引：0
|
作者：
Victoria Wurcel
Diana Chirovsky
Rebekah Borse
Juan Ignacio Altuna
Fernando Carabajal
Jyotika Gandhi
机构：
[1] MSD Argentina,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] CHEORS,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Argentina; Cetuximab; Cost-effectiveness; Head and neck squamous cell carcinoma; Latin America; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2613 / 2630
页数：17
相关论文
共 50 条
  • [21] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
    Yen, C. J.
    Klochikhin, A.
    Cohen, E.
    Vermorken, J.
    Harrington, K.
    Tahara, M.
    Ge, Y.
    Geib, J.
    Jin, F.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
  • [22] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
    Klochikhin, A.
    Greil, R.
    Cohen, E.
    Vermorken, J.
    Harrington, K.
    Tahara, M.
    Ge, J. Y.
    Geib, J.
    Jin, F.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [23] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Swiecicki, Paul
    Rosenberg, Ari J.
    Hanna, Glenn J.
    Bruce, Justine Yang
    Fujisawa, Takao
    Honma, Yoshitaka
    Muro, Kei
    Kaplan, Jason
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Zheng, Dandan
    Hair, Gleicy M.
    Ai, Lei
    Wang, Liya
    Goto, Daisuke
    Lerman, Nati
    Bidadi, Behzad
    Hanna, Glenn J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
    Ito, K.
    Nakanome, A.
    Morita, S.
    Imai, T.
    Asada, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1402 - S1402
  • [26] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CARCINOMA IN PORTUGAL
    Pinheiro, B. A.
    Alarcao, J.
    Silva Miguel, L.
    Huang, M.
    Chandwani, S.
    Vargas Lopes, F.
    Borges, M.
    VALUE IN HEALTH, 2017, 20 (09) : A432 - A432
  • [27] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [28] Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck
    Yokoyama, Kazuki
    Wasano, Koichiro
    Sasaki, Keita
    Machida, Ryunosuke
    Nakahira, Mitsuhiko
    Kitamura, Koji
    Sakagami, Tomofumi
    Takeshita, Naohiro
    Ohkoshi, Akira
    Suzuki, Motoyuki
    Tateya, Ichiro
    Morishita, Yohei
    Sekimizu, Mariko
    Nakayama, Masahiro
    Koyama, Taiji
    Shibata, Hirofumi
    Miyamaru, Satoru
    Kiyota, Naomi
    Hanai, Nobuhiro
    Homma, Akihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1115 - 1122
  • [29] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
    Hu, Man
    Zhang, Shichuan
    Han, Yaqian
    Wu, Hui
    Gao, Jin
    Wu, Haijun
    Lin, Qin
    Shang, Wei
    Li, Xia
    Feng, Hong
    Qiao, Qiao
    Hu, Guangyuan
    Yang, Kunyu
    Song, Xicheng
    Cao, Yuandong
    Kang, Min
    Wang, Ruozheng
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345